Clinical-stage pharmaceutical company Aerie Pharmaceuticals, Inc. recently reported the successful primary efficacy results of its Phase 3 "Mercury 2" trial for its fixed-dose combination product candidate, Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% — a once-daily eye drop that combines Rhopressa™ with latanoprost for lowering IOP in glaucoma patients.
According to Aerie, the 90-day Mercury 2 trial achieved its primary efficacy endpoint of demonstrating statistical superiority over each of its components, including Aerie product candidate Rhopressa (netarsudil ophthalmic solution) 0.02%, and prostaglandin analogue (PGA) latanoprost, all of which were dosed once daily in the evening. The IOP-lowering effect of Roclatan was reportedly 1 to 3 mmHg (millimeters of mercury) greater than monotherapy with either latanoprost or Rhopressa throughout the duration of the study.
Following the results of both the Mercury 1 and Mercury 2 trials, Aerie reportedly plans to submit its NDA for Roclatan in the first half of 2018.
Click here to read the full press release.
Like what you read? Follow OphthalmologyWeb to keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.
Source: Aerie Pharmaceuticals, Inc.